Strong Tech Earnings, Lower Oil Prices Push Stocks to Record Highs

The stock market climbed to record highs on Tuesday, fueled by strong earnings from technology and AI companies, along with a rebound in chip stocks. Meanwhile, oil prices declined amid optimism over a potential U.S.-Iran agreement involving the Strait of Hormuz, helping ease inflation concerns.

Overall, S&P 500 rose 1.8% to 7,737, while Nasdaq jumped 2.6% to 26,585.

Chart of the Day

Here is the one-year chart of Hims & Hers Health (HIMS) as of June 18, 2026, when the stock was at $35.

Hims & Hers has enormous growth opportunity with peptides. Peptides are technically amino acids that act as supplements in a way, and are taken by injection or orally. Peptides can do many things, including help build muscle, act as hormones, help the body heal, treat diabetes, and help with weight loss. However, they can also be dangerous as they can do different things than expected.

In 2023 the FDA put a number of peptides into Category 2, drugs with significant safety risks. So many peptides were forced to sell online in a grey market, with some available at GNC, Amazon, or 503A pharmacies that provide products that not be pure or tested.

Last April, 12 peptides were moved into the safer Category 1. This month, the FDA loosened restrictions on 6 peptides, and Hims & Hers could benefit in a big way. Last year, the company acquired a peptide manufacturing facility, giving it a fully vertical US supply chain. But in last quarter’s earnings call, management sounded cautious on the rollout.

HIMS is on the radar for our Growth Portfolio.

Not a member? Sign up here for $25 a month.